A Prescription for Meaningful Presidential Action
***Press Release***
FOR IMMEDIATE RELEASE July 9, 2019 | Contact: Kate Stotesbery 202-225-4865 |
A Prescription for Meaningful Presidential Action
Washington, D.C. — Today, U.S. Representative Lloyd Doggett (D-TX), Chairman of the Health Subcommittee on Ways and Means, released the following statement in response to President Trump's planned pharmaceutical executive order and a new report from Patients for Affordable Drugs:
"Despite big talk and multiple tweets, Trump has failed to do anything to lower the costs of insulin or other direct consumer drug costs. Some interpret his latest vague executive order as likely limited to government purchases only or to physician-administered drugs only, since he lacks any apparent basis for directly setting consumer drug prices.
For the man always eager to issue an executive order, he can issue one order unilaterally that can make a real difference to many of the sick and dying. He can respond to the still-unanswered April 4, 2017 request by fifty Congressmembers that he restrain prices on drugs developed with taxpayer money. His Administration could significantly lower direct costs on the many pharmaceuticals for which taxpayers have already financed research and development. Today's important report by Patients for Affordable Drugs explains ways that the Administration could implement taxpayer protection through lower drug costs. Meaningful presidential action, with his professed interest in limiting prices to the much lower costs that Big Pharma charges consumers in other major countries, would be to make taxpayer protections part of his order."
Follow Congressman Doggett
Facebook: https://www.Facebook.com/RepLloydDoggett | Twitter: @RepLloydDoggett | Instagram:@RepLloydDoggett